首页 › 基金 › DRIEHAUS CAPITAL MANAGEMENT LLC › XENE
DRIEHAUS CAPITAL MANAGEMENT LLC 对 XENE 的持仓历史
XENON PHARMACEUTICALS INC · 医疗保健
DRIEHAUS CAPITAL MANAGEMENT LLC 在 Q3 2026 的 13F 申报中披露持有 XENE(XENON PHARMACEUTICALS INC)3,557,546 股,市值约 US$132.3M,约占其申报组合的 0.92%,在其申报持仓中市值排名第 17 位。 DRIEHAUS CAPITAL MANAGEMENT LLC 最近 13 个申报季度中有 13 个季度披露了 XENE 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
DRIEHAUS CAPITAL MANAGEMENT LLC 对 XENE 的持仓演变
DRIEHAUS CAPITAL MANAGEMENT LLC 于 Q3 2023 首次披露 XENE 持仓:4,513,005 股(约 US$154.2M)。 该持仓在 Q2 2026 达到峰值 4,418,557 股,市值约 US$266.7M。 在 13 次申报中,DRIEHAUS CAPITAL MANAGEMENT LLC 4 次增持、8 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 3,557,546 股、市值约 US$132.3M,环比减持 -861,011 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 4.51M | $154.16M | 新进 |
| Q4 2023 | 4.35M | $200.14M | 减持 |
| Q1 2024 | 4.32M | $186.05M | 减持 |
| Q2 2024 | 4.42M | $172.32M | 增持 |
| Q3 2024 | 4.60M | $180.93M | 增持 |
| Q4 2024 | 4.52M | $177.21M | 减持 |
| Q1 2025 | 4.58M | $153.82M | 增持 |
| Q2 2025 | 4.34M | $135.71M | 减持 |
| Q3 2025 | 4.17M | $167.39M | 减持 |
| Q4 2025 | 4.54M | $203.42M | 增持 |
| Q1 2026 | 4.49M | $261.19M | 减持 |
| Q2 2026 | 4.42M | $266.70M | 减持 |
| Q3 2026 | 3.56M | $132.31M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 XENE 与 13F 数据
XENE(XENON PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 31 只申报持有 XENE,申报仓位最大的包括:Avoro Capital Advisors LLC (US$204.5M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M), Affinity Asset Advisors, LLC (US$70.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 XENE 的基金
- Avoro Capital Advisors LLC 5.50M 股 · $204.54M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M 股 · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.90M 股 · $70.67M · Q3 2026
- BRAIDWELL LP 1.13M 股 · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K 股 · $53.87M · Q2 2026
- Caligan Partners LP 889.94K 股 · $53.72M · Q2 2026
- Vestal Point Capital, LP 700.00K 股 · $42.25M · Q2 2026
更多关于 DRIEHAUS CAPITAL MANAGEMENT LLC
常见问题
How long has DRIEHAUS CAPITAL MANAGEMENT LLC held XENE?
DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in XENE?
As of Q3 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 3.56M shares of XENE (XENON PHARMACEUTICALS INC), valued at $132.31M, representing 0.92% of its reported portfolio and ranking #17.
Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling XENE?
In the latest 13F filing (Q3 2026), DRIEHAUS CAPITAL MANAGEMENT LLC reduced its position in XENE. The position peaked in Q2 2026 at 4.42M shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DEERFIELD MANAGEMENT COMPANY, L.P., Affinity Asset Advisors, LLC, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.